Cell-bound complement activation products as lupus biomarkers: diagnosis, monitoring and stratification
Sign Up to like & getrecommendations! Published in 2017 at "Expert Review of Clinical Immunology"
DOI: 10.1080/1744666x.2017.1392238
Abstract: ABSTRACT Introduction: Cell-bound complement activation products (CB-CAPs) were first reported in 2004, since which time multiple laboratories have demonstrated their value as biomarkers for diagnosis, monitoring, and stratification of patients with systemic lupus erythematosus. Areas… read more here.
Keywords: medicine; bound complement; biomarkers diagnosis; activation products ... See more keywords